



CLIENT CODE: C000138396

CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

57, Cowley Brown Road, R S Puram

COIMBATORE, 641002 TAMILNADU, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID:

Email: customercare.coimbatore@srl.in

PATIENT NAME: TAMILSELVAN E

TAMIM270390183

ACCESSION NO: **0183VL001199** AGE: 32 Years SEX: Male ABHA NO:

DRAWN: 10/12/2022 00:00 RECEIVED: 10/12/2022 09:25 REPORTED: 14/12/2022 19:41

REFERRING DOCTOR: DR. BANK OF BARODA CLIENT PATIENT ID:

Test Report Status Final Results Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

BLOOD COUNTS,EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	14.1		13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT	4.78		4.5 - 5.5	mil/µL
WHITE BLOOD CELL (WBC) COUNT	6.90		4.0 - 10.0	thou/µL
PLATELET COUNT	217		150 - 410	thou/µL
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	38.6	Low	40 - 50	%
MEAN CORPUSCULAR VOLUME (MCV)	81.0	Low	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	29.5		27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	36.6	High	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	12.7		11.6 - 14.0	%
MENTZER INDEX	17.0			
MEAN PLATELET VOLUME (MPV)	7.1		6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	56		40 - 80	%
LYMPHOCYTES	34		20 - 40	%
MONOCYTES	5		2 - 10	%
EOSINOPHILS	4		1 - 6	%
BASOPHILS	1		< 1 - 2	%
ABSOLUTE NEUTROPHIL COUNT	3.86		2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT	2.35		1.0 - 3.0	thou/µL
ABSOLUTE MONOCYTE COUNT	0.34		0.2 - 1.0	thou/µL
ABSOLUTE EOSINOPHIL COUNT	0.28		0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT	0.07		0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.7			
ERYTHROCYTE SEDIMENTATION RATE (ESR), BLOOD	WHOLE			
E.S.R	9		0 - 14	mm at 1 hr
GLUCOSE FASTING, FLUORIDE PLASMA				
FBS (FASTING BLOOD SUGAR)	85		74 - 99	mg/dL
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA BLOOD	WHOLE			









CLIENT CODE: C000138396

DRAWN: 10/12/2022 00:00

CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

57, Cowley Brown Road, R S Puram

COIMBATORE, 641002 TAMILNADU, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.coimbatore@srl.in

REPORTED:

PATIENT NAME: TAMILSELVAN E

ACCESSION NO: **0183VL001199** AGE: 32 Years SEX: Male A

RECEIVED: 10/12/2022 09:25

ABHA NO:

TAMIM270390183

REFERRING DOCTOR: DR. BANK OF BARODA

CLIENT PATIENT ID:

14/12/2022 19:41

PATIENT ID:

RETHOD: TURBIDIMETRIC IMMUNOINHIBITION (TINIA) ASSAV ESTIMATED AVERAGE GLUCOSE(EAG) METHOD: TURBIDIMETRIC IMMUNOINHIBITION (TINIA) ASSAV ESTIMATED AVERAGE GLUCOSE(EAG) 114.0 114.0 114.0 116.0 mg/dL GLUCOSE, POST-PRANDIAL, PLASMA PPBS(POST PRANDIAL, BLOOD SUGAR) 101 70 - 139 mg/dL LIPID PROFILE, SERUM CHOLESTEROL, TOTAL 149 200 - 239 Borderline High >/= 240 High 200 - 239 Borderline High >/= 240 High TRIGLYCERIDES 73 150 - 199 Borderline High 200 - 439 High >/= 500 Very High method: SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT HDL CHOLESTEROL METHOD: DIRECT MEASURE - PEG CHOLESTEROL LDL 91 43 40 Low >/=60 High mg/dL 100 - 129 Near optimal above optimal and 100 - 129 Near optimal above optimal and 100 - 129 Near optimal above optimal and 100 - 189 High >/= 190 Very High NON HDL CHOLESTEROL 106 CHOL/HDL RATIO 107 3.5 3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk LDL/HDL RATIO 2.1 0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk > 6.0 High Risk	Test Report Status <u>Final</u>	Results	Biological Reference Interval	Units
ESTIMATED AVERAGE GLUCOSE(EAG) 114.0 116.0 mg/dL	HBA1C		Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0	
### CHOLESTEROL LDL ### CHOLESTEROL LDL ### CHOLESTEROL CHOLESTEROL ### CHOLESTEROL LDL ### CHOLESTEROL CHOLESTEROL ### CHOLESTEROL CHOLESTEROL ### CHOLESTEROL CHOLESTEROL ### CHOLESTEROL CHOLESTEROL ### CHOLESTEROL ### CHOLESTEROL ### CHOLESTEROL CHOLESTEROL ### CHOLESTER			< 116.0 mg	a/dl
PRBS(POST PRANDIAL BLOOD SUGAR) LIPID PROFILE, SERUM CHOLESTEROL, TOTAL 149 200 - 239 Borderline High	,	114.0	× 110.0	g/ uL
CHOLESTEROL, TOTAL 149 200 - 239 Borderline High 200 - 499 High 20		101	70 - 139 m	a/dI
CHOLESTEROL, TOTAL 149 200 - 239 Borderline High 200 - 499 High 2		-0-1		9/ ~=
TRIGLYCERIDES 73	CHOLESTEROL, TOTAL	149	200 - 239 Borderline High	g/dL
METHOD : SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT	TRIGLYCERIDES	73	< 150 Normal me 150 - 199 Borderline High 200 - 499 High	g/dL
NETHOD : DIRECT MEASURE - PEG	METHOD: SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT		77-300 very riigh	
CHOLESTEROL LDL 91 < 100 Optimal 100 - 129 Near optimal/ above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High mg/dL NON HDL CHOLESTEROL 106 Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: 90 - 219 Very high: 90 r = 220 mg/dL CHOL/HDL RATIO 3.5 3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk No.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk > 6.0 High Risk	HDL CHOLESTEROL	43	· · · · · · · · · · · · · · · · · · ·	g/dL
NON HDL CHOLESTEROL 106 Desirable: Less than 130 mg/dL Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220 CHOL/HDL RATIO 3.5 3.7 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk LDL/HDL RATIO 2.1 Desirable: Less than 130 mg/dL Above Desirable: Less than 130 mg/dL	CHOLESTEROL LDL	91	100 - 129 Near optimal/ above optimal 130 - 159 Borderline High 160 - 189 High	g/dL
CHOL/HDL RATIO 3.5 3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk No.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	NON HDL CHOLESTEROL	106	Desirable: Less than 130 mg Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219	g/dL
LDL/HDL RATIO 2.1 0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	CHOL/HDL RATIO	3.5	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0	
	LDL/HDL RATIO	2.1	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk	
	VERY LOW DENSITY LIPOPROTEIN	14.6		g/dL

LIVER FUNCTION PROFILE, SERUM









CLIENT CODE: C000138396

CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

57, Cowley Brown Road, R S Puram

COIMBATORE, 641002 TAMILNADU, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.coimbatore@srl.in

PATIENT NAME: TAMILSELVAN E PATIENT ID: TAMIM270390183

ACCESSION NO: **0183VL001199** AGE: 32 Years SEX: Male ABHA NO:

DRAWN: 10/12/2022 00:00 RECEIVED: 10/12/2022 09:25 REPORTED: 14/12/2022 19:41

REFERRING DOCTOR: DR. BANK OF BARODA CLIENT PATIENT ID:

BILIRUBIN, TOTAL 0.90 0.2 - 1.0 mg/dL BILIRUBIN, DIRECT 0.10 0.0 - 0.2 mg/dL BILIRUBIN, INDIRECT 0.8 0.11 - 1.0 mg/dL BILIRUBIN, INDIRECT 0.8 0.1 - 1.0 mg/dL METHOD: BURDETING METHOD METHOR 0.1 0.4 - 8.2 g/dL METHOD: BURDETING METHOD METHOR 0.1 0.3 0.4 - 5.0 g/dL METHOD: BURDING / SPECTOPHOTOMETER GLOBULIN 3 0.0 - 2.1 RATIO ASPARTATE AMINOTRANSFERASE (AST/SGOT) 19 15 - 37 U/L METHOD: UW WITH PYRIDOXAL 5 PHOSPHATE / SPECTROPHOTOMETER ALANINE AMINOTRANSFERASE (ALT/SGOT) 39 < 45.0 U/L METHOD: UW WITH PYRIDOXAL 5 PHOSPHATE / SPECTROPHOTOMETER ALKALINE PHOSPHATASE 8 2 30 - 120 U/L METHOD: UW WITH PYRIDOXAL 5 PHOSPHATE / SPECTROPHOTOMETER ALKALINE PHOSPHATASE 1	Test Report Status <u>Final</u>	Results		Biological Reference	e Interval Units
BILIRUBIN, DIRECT 0.10 0.0 - 0.2 mg/dL BILIRUBIN, INDIRECT 0.8 0.1 - 1.0 mg/dL TOTAL PROTEIN 7.0 6.4 - 8.2 mg/dL TOTAL PROTEIN 7.0 6.4 - 8.2 mg/dL TOTAL PROTEIN 8.0 Mg/dL TOTAL PROTEIN 8.0 Mg/dL METHOD: BURDER PRECTION, END POINT ALBUMIN 4.0 3.4 - 5.0 g/dL METHOD: BURDER PRECTION, END POINT ALBUMIN 3.4 - 5.0 g/dL ALBUMIN/GLOBULIN RATIO 1.3 1.0 - 2.1 RATIO ASPARTATE AMINOTRANSFERASE (AST/SGOT) 19 15 - 37 U/L METHOD: UW WITH PRIDOXAL 5 PHOSPHATE / SPECTROPHOTOMETE ALKALINE PHOSPHATASE 8.2 30 - 120 U/L METHOD: UW WITH PRIDOXAL 5 PHOSPHATE / SPECTROPHOTOMETE ALKALINE PHOSPHATASE (ALT/SGOT) 39 < < 45.0 U/L METHOD: UW WITH PRIDOXAL 5 PHOSPHATE / SPECTROPHOTOMETE ALKALINE PHOSPHATASE (ALT/SGOT) 30 15 - 85 U/L LACTATE DEHYDROGENASE 145 100 - 190 U/L METHOD: LACTATE PRILVATE UW, LACTATE / SPECTROPHOTOMETE BLOOD UREA NITROGEN 8.0 6 - 20 mg/dL CREATININE, SERUM CREATININE, SERUM CREATININE, SERUM URIC ACID 9.20 5.00 - 13.0 mg/dL METHOD: PICKATE/ JAFFE / SPECTROPHOTOMETER BUN/CREAT RATIO 9.20 5.00 - 15.00 URIC ACID 9.6 4 - 8.2 mg/dL TOTAL PROTEIN, SERUM ALBUMIN, SERUM GLOBULIN 3.4 - 5.0 mg/dL METHOD: BURDING / SPECTOPHOTOMETER BURDING SERUP SERIONG / SPECTOPHOTOMETER BURDING SERUP SERIONG / SPECTOPHOTOMETER BURDING SERUM SERIONG /					
BILIRUBIN, INDIRECT 0.8. 0.1 - 1.0	BILIRUBIN, TOTAL	0.90		0.2 - 1.0	mg/dL
TOTAL PROTEIN 7.0 6.4 - 8.2 9/dL METHOD: BUNET REACTION, END POINT ALBUMIN 4.0 3.4 - 5.0 9/dL METHOD: ESP DYE BINDING / SPECTOPHOTOMETER GLOBULIN 3. 1.0 - 2.1 8ATTIO ALBUMIN/GLOBULIN RATIO 1.3 1.0 - 2.1 8ATTIO ASSPARTATE AMINOTRANSFERASE (AST/SGOT) 19 15 - 37 U/L METHOD: UW WITH PRIDDOXAL 5 PHOSPHATE / SPECTROPHOTOMETER ALANINE AMINOTRANSFERASE (ALT/SGPT) 39 45.0 U/L METHOD: UW WITH PRIDDOXAL 5 PHOSPHATE / SPECTROPHOTOMETER ALANINE AMINOTRANSFERASE (ALT/SGPT) 39 45.0 U/L METHOD: UW WITH PRIDDOXAL 5 PHOSPHATE / SPECTROPHOTOMETER ALKALINE PHOSPHATASE BAC 30 - 120 U/L METHOD: LY WITH PRIDDOXAL 5 PHOSPHATE / SPECTROPHOTOMETER ALKALINE PHOSPHATASE BAC 30 - 120 U/L METHOD: LY WITH PRIDDOXAL 5 PHOSPHATE / SPECTROPHOTOMETER BACKLER DEHYSDOGENASE 145 100 - 190 U/L METHOD: LY WITH PRIDDOXAL 5 PHOSPHATE / SPECTROPHOTOMETER BACKLER DEHYSDROGENASE 145 100 - 190 U/L METHOD: LY WITH PRIDDOXAL 5 PHOSPHATE / SPECTOPHOTOMETER BLOOD UREA NITROGEN (BUN), SERUM CREATININE CREATININE BLOOD UREA NITROGEN (BUN), SERUM CREATININE BUN/CREAT RATIO 9.20 0.90 - 1.30 mg/dL METHOD: PICRATE/ JAFFE / SPECTOPHOTOMETER BUN/CREAT RATIO 9.20 5.00 - 15.00 mg/dL TOTAL PROTEIN, SERUM URIC ACID,	BILIRUBIN, DIRECT	0.10		0.0 - 0.2	mg/dL
METHOD : BIURET REACTION, END POINT	BILIRUBIN, INDIRECT	0.8		0.1 - 1.0	mg/dL
ALBUMIN	TOTAL PROTEIN	7.0		6.4 - 8.2	g/dL
######################################	METHOD : BIURET REACTION, END POINT				
STATE STAT	ALBUMIN	4.0		3.4 - 5.0	g/dL
ALBUMIN/GLOBULIN RATIO 1.3 1.0 - 2.1 RATIO ASPARTATE AMINOTRANSFERASE (AST/SGOT) 19 15 - 37 U/L METHOD: UW WITH PYRIDOXAL 5 PHOSPHATE / SPECTROPHOTOMETER ALANINE AMINOTRANSFERASE (ALT/SGPT) 39 45.0 U/L METHOD: UV WITH PYRIDOXAL 5 PHOSPHATE / SPECTROPHOTOMETER ALKALINE PHOSPHATASE 82 30 - 120 U/L METHOD: IPCC PNPP WITH AMP BUFFER GAMMA GLUTAMYL TRANSFERASE (GGT) 30 15 - 85 U/L LACTATE DEHYDROGENASE 145 1000 - 190 U/L METHOD: LACTATE PYRIVATE UV/L LLACTATE / SPECTROPHOTOMETER BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN (BUN) SERUM CREATININE, SERUM CREATININE 920 5.00 - 1.30 mg/dL METHOD: PICRATE/JAFFE / SPECTOPHOTOMETER BUN/CREAT RATIO 9.20 5.00 - 15.00 URIC ACID 5.6 3.5 - 7.2 mg/dL TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN SERUM ALBUMIN SERUM ALBUMIN SERUM ALBUMIN SERUM ALBUMIN A.0 3.4 - 5.0 g/dL METHOD: BCP DYE BINDING / SPECTOPHOTOMETER BURCHOD: BCP DYE BINDING / SPECTOPHOTOMETER GLOBULIN GLOBULIN 3 2.0 - 4.11 g/dL g/dL	METHOD : BCP DYE BINDING / SPECTOPHOTOMETER				
ASPARTATE AMINOTRANSFERASE (AST/SGOT) 19 15 - 37 U/L METHOD: UV WITH PYRIDOXAL 5 PHOSPHATE / SPECTROPHOTOMETER ALANINE AMINOTRANSFERASE (ALT/SGPT) 39 < 45.0 U/L METHOD: UV WITH PYRIDOXAL 5 PHOSPHATE / SPECTROPHOTOMETER KLKALINE PHOSPHATASE 82 30 - 120 U/L METHOD: IPCC PNPP WITH AMP BUFFER 82	GLOBULIN	3		2.0 - 4.1	g/dL
METHOD: UV WITH PYRIDOXAL 5 PHOSPHATE / SPECTROPHOTOMETER ALANINE AMINOTRANSFERASE (ALT/SGPT) 39 < 45.0	ALBUMIN/GLOBULIN RATIO	1.3		1.0 - 2.1	RATIO
ALANINE AMINOTRANSFERASE (ALT/SGPT) 39 45.0 U/L METHOD: UV WITH PYRIDOXAL 5 PHOSPHATE / SPECTROPHOTOMETE* ALKALINE PHOSPHATASE 82 30 - 120 U/L METHOD: IFCC PNPP WITH AMP BUFFER SAMMA GLUTAMYL TRANSFERASE (GGT) 30 15 - 85 U/L LACTATE DEHYDROGENASE 145 100 - 190 U/L METHOD: LACTATE PYRUVATE UV/ LLACTATE / SPECTOPHOTOMETE* BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN 8 6- 20 mg/dL CREATININE, SERUM CREATININE, SERUM CREATININE 9.20 0.90 - 1.30 mg/dL METHOD: PICRATE/ JAFFE / SPECTOPHOTOMETER BUN/CREAT RATIO 9.20 5.00 - 15.00 mg/dL BUN/CREAT RATIO 9.20 5.00 - 15.00 mg/dL TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM GLOBULIN 30 34 - 5.0 g/dL BCIOBULIN 9, G/dL BCIOBULI	ASPARTATE AMINOTRANSFERASE (AST/SGOT)	19		15 - 37	U/L
METHOD: UV WITH PYRIDOXAL 5 PHOSPHATE / SPECTROPHOTOMETE / ALKALINE PHOSPHATASE 82 30 - 120 U/L METHOD: IFCC PNEP WITH AMP BUFFER GAMMA GLUTAMYL TRANSFERASE (GGT) 30 15 - 85 U/L LACTATE DEHYDROGENASE 145 100 - 190 U/L METHOD: LACTATE PYRIVATE UV/ LLACTATE / SPECTOPHOTOMETER BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN (BUN), SERUM CREATININE, SERUM CREATININE, SERUM CREATININE 90.87 Low 0.90 - 1.30 mg/dL METHOD: PICRATE/ JAFFE / SPECTOPHOTOMETER BUN/CREAT RATIO 9.20 5.00 - 15.00 URIC ACID, SERUM URIC ACID, SERUM URIC ACID 5.66 3.5 - 7.2 mg/dL TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM GLOBULIN GLOBULIN GLOBULIN GLOBULIN B2 2.0 - 4.1 mg/dL 9/dL 10 9/dL	METHOD: UV WITH PYRIDOXAL 5 PHOSPHATE / SPECTROPHOTOI	METER			
ALKALINE PHOSPHATASE METHOD: IFCC PNPP WITH AMP BUFFER GAMMA GLUTAMYL TRANSFERASE (GGT) 100-190 101	ALANINE AMINOTRANSFERASE (ALT/SGPT)	39		< 45.0	U/L
METHOD::FCC PNPP WITH AMP BUFFER GAMMA GLUTAMYL TRANSFERASE (GGT) 145 LACTATE DEHYDROGENASE 145 140 - 190 U/L METHOD::LACTATE PYRUVATE UV/ LLACTATE / SPECTOPHOTOMETER BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN BLOOD UREA	METHOD: UV WITH PYRIDOXAL 5 PHOSPHATE / SPECTROPHOTOI	METER			
GAMMA GLUTAMYL TRANSFERASE (GGT) 30 15 - 85 U/L LACTATE DEHYDROGENASE 145 100 - 190 U/L BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN 8 6 - 20 mg/dL CREATININE, SERUM CREATININE 0.87 Low 0.90 - 1.30 mg/dL MICHADO : PICRATE/ JAFFE / SPECTOPHOTOMETER 5 5.00 - 15.00 mg/dL BUN/CREAT RATIO 9.20 5.00 - 15.00 mg/dL URIC ACID, SERUM URIC ACID, SERUM 3.5 - 7.2 mg/dL TOTAL PROTEIN, SERUM 6.4 - 8.2 g/dL TOTAL PROTEIN, SERUM 7.0 6.4 - 8.2 g/dL ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN SERUM ALBUMIN SERUM ALBUMIN SERUM ALBUMIN SERUM <td>ALKALINE PHOSPHATASE</td> <td>82</td> <td></td> <td>30 - 120</td> <td>U/L</td>	ALKALINE PHOSPHATASE	82		30 - 120	U/L
LACTATE DEHYDROGENASE 145 100 - 190 U/L BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN 8 6 - 20 mg/dL CREATININE, SERUM CREATININE 0.87 Low 0.90 - 1.30 mg/dL BUN/CREATE JAFFE / SPECTOPHOTOMETER BUN/CREAT RATIO 9.20 5.00 - 15.00 TOTAL PROTEIN TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM A.9 3.5 - 7.2 mg/dL TOTAL PROTEIN, SERUM 7.0 6.4 - 8.2 g/dL g/dL ALBUMIN, SERUM 4.0 3.4 - 5.0 g/dL ALBUMIN, SERUM 4.0 3.4 - 5.0 g/dL METHOD : BCP DYE BINDING / SPECTOPHOTOMETER 5.6 2.0 - 4.1 g/dL	METHOD : IFCC PNPP WITH AMP BUFFER				
METHOD: LACTATE PYRUVATE UV/ LIACTATE / SPECTOPHOTOMETER BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN 8 6 - 20 mg/dL CREATININE, SERUM CREATININE 0.87 Low 0.90 - 1.30 mg/dL METHOD: PICRATE/ JAFFE / SPECTOPHOTOMETER V 5.00 - 1.30 mg/dL BUN/CREAT RATIO 9.20 5.00 - 15.00 V URIC ACID, SERUM V 3.5 - 7.2 mg/dL TOTAL PROTEIN, SERUM 7.0 6.4 - 8.2 g/dL METHOD: BIURET REACTION, END POINT 4 0.4 - 8.2 g/dL ALBUMIN, SERUM 4.0 3.4 - 5.0 g/dL METHOD: BICP PISHDING / SPECTOPHOTOMETER 4 5.0 4.1 5.0 9/dL	GAMMA GLUTAMYL TRANSFERASE (GGT)	30		15 - 85	U/L
BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN 8 6 - 20 mg/dL CREATININE, SERUM CREATININE 0.87 Low 0.90 - 1.30 mg/dL METHOD: PICRATE/ JAFFE / SPECTOPHOTOMETER BUN/CREAT RATIO 9.20 5.00 - 15.00 TURE CACID, SERUM TURIC ACID, SERUM TURIC ACID 3.5 - 7.2 mg/dL Mg/dL TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM 6.4 - 8.2 g/dL Mg/dL ALBUMIN, SERUM 4.0 3.4 - 5.0 g/dL Mg/dL	LACTATE DEHYDROGENASE	145		100 - 190	U/L
BLOOD UREA NITROGEN 8 6 - 20 mg/dL CREATININE, SERUM CREATININE 0.87 Low 0.90 - 1.30 mg/dL METHOD : PICRATE/ JAFFE / SPECTOPHOTOMETER BUN/CREAT RATIO 9.20 5.00 - 15.00 URIC ACID, SERUM URIC ACID, SERUM URIC ACID 5.6 3.5 - 7.2 mg/dL TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN 4.0 3.4 - 5.0 g/dL METHOD : BICP DYE BINDING / SPECTOPHOTOMETER GLOBULIN GLOBULIN 3 3.0 - 4.1 g/dL	METHOD: LACTATE PYRUVATE UV/ L.LACTATE / SPECTOPHOTOME	ETER			
CREATININE, SERUM CREATININE 0.87 Low 0.90 - 1.30 mg/dL METHOD: PICRATE/ JAFFE / SPECTOPHOTOMETER BUN/CREAT RATIO 9.20 5.00 - 15.00 BUN/CREAT RATIO 9.20 5.00 - 15.00 URIC ACID, SERUM TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM 7.0 6.4 - 8.2 g/dL ALBUMIN, SERUM 4.0 3.4 - 5.0 g/dL ALBUMIN SERUM 4.0 3.4 - 5.0 g/dL METHOD: BCP DYE BINDING / SPECTOPHOTOMETER GLOBULIN 3.0 - 4.1 g/dL	BLOOD UREA NITROGEN (BUN), SERUM				
CREATININE METHOD: PICRATE/ JAFFE / SPECTOPHOTOMETER BUN/CREAT RATIO BUN	BLOOD UREA NITROGEN	8		6 - 20	mg/dL
METHOD: PICRATE/ JAFFE / SPECTOPHOTOMETER BUN/CREAT RATIO BUN/CREAT RATIO BUN/CREAT RATIO 9.20 5.00 - 15.00 URIC ACID, SERUM URIC ACID S.6 3.5 - 7.2 mg/dL TOTAL PROTEIN, SERUM TOTAL PROTEIN TOTAL PROTEIN ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN 4.0 METHOD: BCP DYE BINDING / SPECTOPHOTOMETER GLOBULIN GLOBULIN 3.0 - 4.1 g/dL	CREATININE, SERUM				
BUN/CREAT RATIO BUN/CREAT RATIO 9.20 5.00 - 15.00 URIC ACID, SERUM URIC ACID 5.6 3.5 - 7.2 mg/dL TOTAL PROTEIN, SERUM TOTAL PROTEIN 7.0 6.4 - 8.2 g/dL METHOD: BIURET REACTION, END POINT 4.0 3.4 - 5.0 g/dL ALBUMIN, SERUM 4.0 3.4 - 5.0 g/dL METHOD: BCP DYE BINDING / SPECTOPHOTOMETER GLOBULIN 2.0 - 4.1 g/dL	CREATININE	0.87	Low	0.90 - 1.30	mg/dL
BUN/CREAT RATIO 9.20 5.00 - 15.00 URIC ACID, SERUM TOTAL PROTEIN, SERUM 7.0 6.4 - 8.2 g/dL METHOD: BIURET REACTION, END POINT 7.0 6.4 - 8.2 g/dL ALBUMIN, SERUM ALBUMIN, SERUM 4.0 3.4 - 5.0 g/dL METHOD: BCP DYE BINDING / SPECTOPHOTOMETER GLOBULIN GLOBULIN 2.0 - 4.1 g/dL	METHOD: PICRATE/ JAFFE / SPECTOPHOTOMETER				
URIC ACID, SERUM URIC ACID 5.6 5.6 3.5 - 7.2 mg/dL TOTAL PROTEIN, SERUM TOTAL PROTEIN METHOD: BIURET REACTION, END POINT ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN ALBUMIN BURDET BENDING / SPECTOPHOTOMETER GLOBULIN 3.0 - 4.1 g/dL	BUN/CREAT RATIO				
URIC ACID TOTAL PROTEIN, SERUM TOTAL PROTEIN METHOD: BURET REACTION, END POINT ALBUMIN, SERUM ALBUMIN SERUM ALBUMIN SERUM GLOBULIN GLOBULIN 5.6 3.5 - 7.2 Medd	BUN/CREAT RATIO	9.20		5.00 - 15.00	
URIC ACID TOTAL PROTEIN, SERUM TOTAL PROTEIN METHOD: BURET REACTION, END POINT ALBUMIN, SERUM ALBUMIN SERUM ALBUMIN SERUM GLOBULIN GLOBULIN 5.6 3.5 - 7.2 Medd	URIC ACID, SERUM				
TOTAL PROTEIN, SERUM TOTAL PROTEIN 7.0 6.4 - 8.2 g/dL METHOD: BIURET REACTION, END POINT ALBUMIN, SERUM ALBUMIN ALBUMIN BLOBULIN 3.4 - 5.0 g/dL g/dL g/dL g/dL		5.6		3.5 - 7.2	ma/dL
TOTAL PROTEIN METHOD: BIURET REACTION, END POINT ALBUMIN, SERUM ALBUMIN METHOD: BCP DYE BINDING / SPECTOPHOTOMETER GLOBULIN GLOBULIN 7.0 6.4 - 8.2 g/dL 9/dL 9/dL 9/dL		5.5		0.0 7.1	9, 4=
METHOD: BIURET REACTION, END POINT ALBUMIN, SERUM ALBUMIN 4.0 3.4 - 5.0 g/dL METHOD: BCP DYE BINDING / SPECTOPHOTOMETER GLOBULIN 3 2.0 - 4.1 g/dL	-	7.0		64-82	a/dl
ALBUMIN, SERUM ALBUMIN 4.0 3.4 - 5.0 g/dL METHOD: BCP DYE BINDING / SPECTOPHOTOMETER GLOBULIN 3 2.0 - 4.1 g/dL		7.0		0.4 0.2	g/uL
ALBUMIN 4.0 3.4 - 5.0 g/dL METHOD: BCP DYE BINDING / SPECTOPHOTOMETER GLOBULIN 3 2.0 - 4.1 g/dL					
METHOD: BCP DYE BINDING / SPECTOPHOTOMETER GLOBULIN 3 2.0 - 4.1 g/dL		4 0		34-50	a/dl
GLOBULIN 3 2.0 - 4.1 g/dL		ਜ. ∪		J. T J.U	g/uL
GLOBULIN 3 2.0 - 4.1 g/dL	· ·				
		3		2 0 - 4 1	a/dl
		J		Z.U - 4.1	y/uL



Page 3 Of 12





CLIENT CODE: C000138396

CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd

57, Cowley Brown Road, R S Puram

COIMBATORE, 641002 TAMILNADU, İNDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.coimbatore@srl.in

PATIENT NAME: TAMILSELVAN E PATIENT ID: TAMIM270390183

ACCESSION NO: 0183VL001199 AGE: 32 Years SEX: Male ABHA NO:

DRAWN: 10/12/2022 00:00 RECEIVED: 10/12/2022 09:25 14/12/2022 19:41 REPORTED:

REFERRING DOCTOR: DR. BANK OF BARODA CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference Interva	l Units		
CODILIM CEDIM	135.2 Low	136 - 145	mmal/l		
SODIUM, SERUM	4.37		mmol/L		
POTASSIUM, SERUM		3.50 - 5.10	mmol/L		
CHLORIDE, SERUM	104.0	98 - 107	mmol/L		
PHYSICAL EXAMINATION, URINE	DALE VELLOW				
COLOR	PALE YELLOW				
APPEARANCE	CLEAR				
CHEMICAL EXAMINATION, URINE	6.5	4.7.7.5			
PH	6.5	4.7 - 7.5			
SPECIFIC GRAVITY	1.015	1.003 - 1.035			
PROTEIN	NOT DETECTED	NOT DETECTED			
GLUCOSE	NOT DETECTED	NOT DETECTED			
KETONES	NOT DETECTED	NOT DETECTED			
BLOOD	NOT DETECTED	NOT DETECTED			
BILIRUBIN	NOT DETECTED	NOT DETECTED			
UROBILINOGEN	NORMAL	NORMAL			
NITRITE	NOT DETECTED	NOT DETECTED			
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED			
MICROSCOPIC EXAMINATION, URINE					
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF		
PUS CELL (WBC'S)	2-3	0-5	/HPF		
EPITHELIAL CELLS	2-3	0-5	/HPF		
CASTS	NOT DETECTED				
CRYSTALS	NOT DETECTED				
BACTERIA	NOT DETECTED	NOT DETECTED			
YEAST	NOT DETECTED	NOT DETECTED			
Comments					
URINALYSIS :- MICROSCOPIC EXAMINATION OF URINE IS CARRIED OUT ON CENTRIFUGED URINARY SEDIMENT. THYROID PANEL, SERUM					
ТЗ	128.7	80.00 - 200.00	ng/dL		

T3	128.7	80.00 - 200.00	ng/dL
METHOD: ELECTROCHEMILUMINESCENCE IMMUNO ASSAY			
T4	6.98	5.10 - 14.10	μg/dL
METHOD: ELECTROCHEMILUMINESCENCE IMMUNO ASSAY			
TSH (ULTRASENSITIVE)	1.800	0.270 - 4.200	μIU/mL

METHOD: ELECTROCHEMILUMINESCENCE IMMUNO ASSAY









CLIENT CODE: C000138396 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030 DELHI INDIA** 8800465156

57, Cowley Brown Road, R S Puram

COIMBATORE, 641002 TAMILNADU, İNDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.coimbatore@srl.in

PATIENT NAME: TAMILSELVAN E

TAMIM270390183

ACCESSION NO: 0183VL001199

AGE: 32 Years SEX: Male ABHA NO: REPORTED:

14/12/2022 19:41

DRAWN: 10/12/2022 00:00

REFERRING DOCTOR: DR. BANK OF BARODA

RECEIVED: 10/12/2022 09:25

CLIENT PATIENT ID:

PATIENT ID:

Test Report Status

<u>Final</u>

Results

Biological Reference Interval Units

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyporthyroidism, TSH levels are low. owidctlparowidctlparBelow mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

PHYSICAL EXAMINATION, STOOL

COLOUR BROWN

CONSISTENCY WELL FORMED

MUCUS NOT DETECTED NOT DETECTED

VISIBLE BLOOD ABSENT ABSENT

ADULT PARASITE NOT DETECTED









CLIENT CODE: C000138396 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030 DELHI INDIA** 8800465156

SRL Ltd

57, Cowley Brown Road, R S Puram

COIMBATORE, 641002 TAMILNADU, İNDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.coimbatore@srl.in

PATIENT NAME: TAMILSELVAN E PATIENT ID: TAMIM270390183

ACCESSION NO: 0183VL001199 AGE: 32 Years SEX: Male ABHA NO:

DRAWN: 10/12/2022 00:00 RECEIVED: 10/12/2022 09:25 REPORTED: 14/12/2022 19:41

REFERRING DOCTOR: DR. BANK OF BARODA CLIENT PATIENT ID:

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

CHEMICAL EXAMINATION, STOOL

STOOL PH **ACIDIC**

OCCULT BLOOD NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, STOOL

PUS CELLS 0 - 1/hpf

NOT DETECTED /HPF **RED BLOOD CELLS** NOT DETECTED

NOT DETECTED NOT DETECTED **CYSTS**

OVA NOT DETECTED

LARVAE NOT DETECTED NOT DETECTED NOT DETECTED **TROPHOZOITES** NOT DETECTED

FAT **ABSENT** VEGETABLE CELLS **ABSENT**

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE B RH TYPE **POSITIVE**

XRAY-CHEST

BOTH THE LUNG FIELDS ARE CLEAR **>>**

BOTH THE COSTOPHRENIC AND CARIOPHRENIC ANGELS ARE CLEAR **»**»

BOTH THE HILA ARE NORMAL **>>**

CARDIAC AND AORTIC SHADOWS APPEAR NORMAL **>>** BOTH THE DOMES OF THE DIAPHRAM ARE NORMAL **>>**

VISUALIZED BONY THORAX IS NORMAL **»**»

NO ABNORMALITY DETECTED **IMPRESSION**

TMT OR ECHO

TMT OR ECHO TMT DONE

ECG

WITHIN NORMAL LIMITS **ECG**

MEDICAL HISTORY

RELEVANT PRESENT HISTORY NOT SIGNIFICANT RELEVANT PAST HISTORY NOT SIGNIFICANT

RELEVANT PERSONAL HISTORY **MARRIED**

RELEVANT FAMILY HISTORY MOTHER H/O DM OCCUPATIONAL HISTORY NOT SIGNIFICANT HISTORY OF MEDICATIONS NOT SIGNIFICANT



Page 6 Of 12 Scan to View Report





CLIENT CODE: C000138396
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

57, Cowley Brown Road, R S Puram

COIMBATORE, 641002 TAMILNADU, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.coimbatore@srl.in

PATIENT NAME: TAMILSELVAN E PATIENT ID: TAMIM270390183

ACCESSION NO: **0183VL001199** AGE: 32 Years SEX: Male ABHA NO:

DRAWN: 10/12/2022 00:00 RECEIVED: 10/12/2022 09:25 REPORTED: 14/12/2022 19:41

REFERRING DOCTOR: DR. BANK OF BARODA CLIENT PATIENT ID:

Test Report Status Final Results Biological Reference Interval Units

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.79 mts
WEIGHT IN KGS. 80 Kgs
BMI 25 BMI & Weight Status as follows: kg/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

NORMAL MENTAL / EMOTIONAL STATE PHYSICAL ATTITUDE **NORMAL** GENERAL APPEARANCE / NUTRITIONAL STATUS **OVERWEIGHT BUILT / SKELETAL FRAMEWORK AVERAGE** FACIAL APPEARANCE NORMAL SKIN **NORMAL** UPPER LIMB **NORMAL** LOWER LIMB **NORMAL NECK NORMAL**

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND NOT ENLARGED

CAROTID PULSATION NORMAL BREAST (FOR FEMALES) NORMAL TEMPERATURE NORMAL

PULSE 64/MINS, REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID

BRUIT

RESPIRATORY RATE NORMAL

CARDIOVASCULAR SYSTEM

BP 120/70 MM HG mm/Hg (SΙΤΠΝG)

PERICARDIUM NORMAL
APEX BEAT NORMAL
HEART SOUNDS NORMAL
MURMURS ABSENT

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST NORMAL

MOVEMENTS OF CHEST SYMMETRICAL

BREATH SOUNDS INTENSITY NORMAL









CLIENT CODE: C000138396
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

57, Cowley Brown Road, R S Puram

COIMBATORE, 641002 TAMILNADU, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.coimbatore@srl.in

PATIENT NAME: TAMILSELVAN E PATIENT ID: TAMIM270390183

ACCESSION NO: **0183VL001199** AGE: 32 Years SEX: Male ABHA NO:

DRAWN: 10/12/2022 00:00 RECEIVED: 10/12/2022 09:25 REPORTED: 14/12/2022 19:41

REFERRING DOCTOR: DR. BANK OF BARODA CLIENT PATIENT ID:

Test Report Status Final Results Biological Reference Interval Units

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS ABSENT

PER ABDOMEN

APPEARANCE NORMAL VENOUS PROMINENCE ABSENT

LIVER NOT PALPABLE SPLEEN NOT PALPABLE

HERNIA NORMAL

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS NORMAL
CRANIAL NERVES NORMAL
CEREBELLAR FUNCTIONS NORMAL
SENSORY SYSTEM NORMAL
MOTOR SYSTEM NORMAL
REFLEXES NORMAL

MUSCULOSKELETAL SYSTEM

SPINE NORMAL JOINTS NORMAL

BASIC EYE EXAMINATION

CONJUNCTIVA **NORMAL EYELIDS NORMAL** EYE MOVEMENTS **NORMAL** CORNEA **NORMAL** DISTANT VISION RIGHT EYE WITHOUT GLASSES 6/6 DISTANT VISION LEFT EYE WITHOUT GLASSES 6/6 NEAR VISION RIGHT EYE WITHOUT GLASSES N/6 NEAR VISION LEFT EYE WITHOUT GLASSES N/6

BASIC ENT EXAMINATION

COLOUR VISION

EXTERNAL EAR CANAL

TYMPANIC MEMBRANE

NORMAL

NOSE NO ABNORMALITY DETECTED

NORMAL

SINUSES CLEAR

THROAT NO ABNORMALITY DETECTED









TAMIM270390183

CLIENT CODE: C000138396 **CLIENT'S NAME AND ADDRESS:**

DRAWN: 10/12/2022 00:00

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030 DELHI INDIA** 8800465156

SRL Ltd

57, Cowley Brown Road, R S Puram

COIMBATORE, 641002 TAMILNADU, İNDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID:

CLIENT PATIENT ID:

14/12/2022 19:41

Email: customercare.coimbatore@srl.in

REPORTED:

PATIENT NAME: TAMILSELVAN E

REFERRING DOCTOR: DR. BANK OF BARODA

ACCESSION NO: 0183VL001199 AGE: 32 Years SEX: Male ABHA NO:

RECEIVED: 10/12/2022 09:25

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

TONSILS NOT FNI ARGED

BASIC DENTAL EXAMINATION

TEETH NORMAL **GUMS HEALTHY**

SUMMARY

RELEVANT HISTORY NOT SIGNIFICANT RELEVANT GP EXAMINATION FINDINGS NOT SIGNIFICANT

WITHIN NORMAL LIMITS RELEVANT LAB INVESTIGATIONS

RELEVANT NON PATHOLOGY DIAGNOSTICS NO ABNORMALITIES DETECTED

REMARKS / RECOMMENDATIONS NONE

FITNESS STATUS

FITNESS STATUS FIT (AS PER REQUESTED PANEL OF TESTS)

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait. wBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4 (2010) and NLR = 3.5 (2010) and NLR = 3.5 (2010) and NLR = 3.5 (2010) and NLR = 3.6 (2010) and NLR = 3.7 (2010) and NLR = 3.7 (2010) and NLR = 3.8 (2010) and NLR = 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2, Paediatric reference intervals, AACC Press, 7th edition, Edited by S. Soldin 3, The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the









CLIENT CODE: C000138396

CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030 DELHI INDIA** 8800465156

SRL Ltd

57, Cowley Brown Road, R S Puram

COIMBATORE, 641002 TAMILNADU, ÍNDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.coimbatore@srl.in

PATIENT NAME: TAMILSELVAN E

ACCESSION NO: 0183VL001199 AGE: 32 Years SEX: Male ABHA NO:

TAMIM270390183

Units

DRAWN: 10/12/2022 00:00

Test Report Status

RECEIVED: 10/12/2022 09:25

REPORTED: 14/12/2022 19:41

PATIENT ID:

REFERRING DOCTOR: DR. BANK OF BARODA

<u>Final</u>

CLIENT PATIENT ID:

Biological Reference Interval

urine.

Increased in Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin,insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol sulfonylureas,tolbutamide, and other oral hypoglycemic agents **NOTE:**

Results

Hypoglycemia is defined as a glucoseof < 50 mg/dL in men and < 40 mg/dL in women.

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus,

While failed in Serum glucose levels correlate with nome glucose monitoring results (weekly mean capillary glucose values), there is wide nucleated within individuals. This glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2.Diagnosing diabetes.
- 3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- 1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
- 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

II. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, is chemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction,

Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget''s disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy to. Againmagneously (lethorhage), but may be disease, Malasso profit synthetic synthet

Causes of decreased level include Liver disease, SIADH.
CREATININE, SERUM-Higher than normal level may be due to:









CLIENT CODE: C000138396

CLIENT'S NAME AND ADDRESS: ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030 DELHI INDIA** 8800465156

SRL Ltd

57, Cowley Brown Road, R S Puram

COIMBATORE, 641002 TAMILNADU, İNDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.coimbatore@srl.in

PATIENT NAME: TAMILSELVAN E

AGE: 32 Years SEX: Male PATIENT ID: TAMIM270390183

0183VL001199 ACCESSION NO: ABHA NO:

DRAWN: 10/12/2022 00:00 RECEIVED: 10/12/2022 09:25 REPORTED: 14/12/2022 19:41

REFERRING DOCTOR: DR. BANK OF BARODA CLIENT PATIENT ID:

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

• Blockage in the urinary tract

- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
 Loss of body fluid (dehydration)

- Muscle problems, such as breakdown of muscle fibers
 Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

• Muscular dystrophy
URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic

Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom"""""""" disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

FITNESS STATUS-

Conclusion on an individual's Fitness, which is commented upon mainly for Pre employment cases, is based on multi factorial findings and does not depend on any one single parameter. The final Fitness assigned to a candidate will depend on the Physician's findings and overall judgement on a case to case basis, details of the candidate's past and personal history as well as the comprehensiveness of the diagnostic panel which has been requested for .These are then further correlated with details of the job under consideration to eventually fit the right man to the right job.

Basis the above, SRL classifies a candidate's Fitness Status into one of the following categories:

- Fit (As per requested panel of tests) SRL Limited gives the individual a clean chit to join the organization, on the basis of the General Physical Examination and the specific test panel requested for.
- Fit (with medical advice) (As per requested panel of tests) This indicates that although the candidate can be declared as FIT to join the job, minimal problems have been detected during the Pre- employment examination. Examples of conditions which could fall in this category could be cases of mild reversible medical abnormalities such as height weight disproportions, borderline raised Blood Pressure readings, mildly raised Blood sugar and Blood Lipid levels, Hematuria, etc. Most of these relate to sedentary
- iffestyles and come under the broad category of life style disorders. The idea is to caution an individual to bring about certain lifestyle changes as well as seek a Physician's consultation and counseling in order to bring back to normal the mildly deranged parameters. For all purposes the individual is FIT to join the job.

 Fitness on Hold (Temporary Unfit) (As per requested panel of tests) Candidate's reports are kept on hold when either the diagnostic tests or the physical findings reveal the presence of a medical condition which warrants further tests, counseling and/or specialist opinion, on the basis of which a candidate can either be placed into Fit, Fit (With Medical Advice), or Unfit category. Conditions which may fall into this category could be high blood pressure, abnormal ECG, heart murmurs, abnormal vision, grossly
- elevated blood sugars, etc.

 Unfit (As per requested panel of tests) An unfit report by SRL Limited clearly indicates that the individual is not suitable for the respective job profile e.g. total color blindness in color related jobs.









CLIENT CODE: C000138396
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

57, Cowley Brown Road, R S Puram

COIMBATORE, 641002 TAMILNADU, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.coimbatore@srl.in

PATIENT NAME: TAMILSELVAN E

PATIENT ID : **TAMIM270390183**

ACCESSION NO: **0183VL001199** AGE: 32 Years SEX: Male ABHA NO:

DRAWN: 10/12/2022 00:00 RECEIVED: 10/12/2022 09:25 REPORTED: 14/12/2022 19:41

REFERRING DOCTOR: DR. BANK OF BARODA CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Units

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ULTRASOUND ABDOMEN
ULTRASOUND ABDOMEN
GRADE I PROSTATOMEGALY

End Of Report
Please visit www.srlworld.com for related Test Information for this accession



CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



